PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:25-1:50 |
| Pretreatment | HistoZyme |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Cytokeratin 20 Information for Pathologists
Summary:
Epithelial marker (MW 46 kDa) with restricted expression compared to CK7 (OMIM #608218). Uses by pathologists General patterns (specificity varies). CK7+ / CK20+ in carcinomas of bile duct (extrahepatic / gallbladder, often, Pathol Res Pract 2003;199:65), lung-mucinous bronchioloalveolar (Am J Clin Pathol 2004;122:421), pancreas (Cancer 2006;106:693, but see Arch Pathol Lab Med 2000;124:1196). Urothelium (often, Arch Pathol Lab Med 2001;125:921, Hum Pathol 2002;33:1136).
Common Uses By Pathologists:
General patterns (specificity varies). CK7+ / CK20+ in carcinomas of bile duct (extrahepatic / gallbladder, often, Pathol Res Pract 2003;199:65), lung-mucinous bronchioloalveolar (Am J Clin Pathol 2004;122:421), pancreas (Cancer 2006;106:693, but see Arch Pathol Lab Med 2000;124:1196). Urothelium (often, Arch Pathol Lab Med 2001;125:921, Hum Pathol 2002;33:1136). Also primary mucinous tumors of ovary (74%), upper GI tract (78%) and endocervix (88%, Am J Surg Pathol 2006;30:1130). CK7+ / CK20- in carcinomas of bile duct (intrahepatic, Pathol Res Pract 2003;199:65), breast (Ann Diagn Pathol 1999;3:350), endocervical and endometrial adenocarcinoma (Pathol Res Pract 2003;199:65), esophagus (distal, Am J Surg Pathol 2002;26:1213), lung (not mucinous bronchioloalveolar, BMC Cancer 2006;6:31), salivary gland (Pathol Int 2005;55:386), thyroid (Appl Immunohistochem Mol Morphol 2000;8:189).
| Cytokeratin 20 General Information | |
|---|---|
| Alternate Names | |
| Molecular Weight | |
| 48.5 kDa | |
| Chromosomal Location | |
| [chr: CHR_HSCHR17_4_CTG4] [chr_start: 40875941] [chr_end: 40885227] [strand: -1]; q21.2 [chr: 17] [chr_start: 40875941] [chr_end: 40885227] [strand: -1] | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | KRT20 |
| Entrez Gene ID | 54474 |
| RefSeq Protein Accession(s) | NP_061883 |
| RefSeq mRNA Accession(s) | NM_019010; |
| RefSeq Genomic Accession(s) | NW_003871091; NG_012286; NC_000017 |
| UniProt ID(s) | P35900 |
| PharmGKB ID(s) | PA134938907 |
| KEGG Gene ID(s) | hsa:54474 |
| General Description of Cytokeratin 20 . | |
| Cytokeratin 20 is less acidic than the other type I cytokeratins and is of particular interest because of its restricted range of expression. This antibody reacts with cytokeratin polypeptide of 46 kDa in immunoblot analyses. Studies have shown that a marked difference exists in the expression of Cytokeratin 20 among various carcinomas. | |
There are no reviews yet.